Abstract:When not treated properly, Rheumatoid arthritis (RA) progresses in its chronic course, joint damage increases, and it can even lead to systemic involvement. Methotrexate (MTX), is the most preferred drug in RA treatment. However, there is no agreement among physicians on the dose of methotrexate. The aim of this study was to determine the effects and side effects of high dose methotrexate use in the initial combined therapy on the activity of disease among active RA patients. Newly diagnosed 45 RA patients were divided into two groups randomly. First group received 12,5 mg/week MTX im for four weeks and continued orally. Second group received 25 mg/week MTX im for four weeks and continued with 12,5 mg/week orally. Beside the MTX treatment, 2 gr/day SLZ and 5 mg/day prednisolone were given to both groups. At three different stages of the treatment patients were evaluated in terms of DAS28, MHAQ, VAS, morning stiffness, ESR and CRP. Patients were 34 female and 11 male. Mean disease duration was 14.7 months. In 1st group, mean DAS28 was 6.51 at the beginning, and in the end of the 3rd month it decreased to 2.75. In second group, mean DAS28 was 6.05 at the beginning, and in the end of the 3rd month it decreased to 3.56. Tender joint count in second group was 3.17 at the 3rd month, whereas it was 1.64 at the first group. In the 3rd month, at the high dose MTX group, VAS, DAS28 showed statistically significant improvement when compared to parameters of other group. CRP, morning stiffness, swollen joint count, and MHAQ scores at the 25mg/week MTX group were better at the 1st and 3rd months; however, there was no statistically significant difference between two groups in terms of those parameters. Three patients had nausea, fatigue, vomiting. At the 3rd month, at first group treatment was changed in one patient only. At second group, treatment was changed in 4 patients. In one patient, nausea and vomiting developed and ALT increased in another patient. Although scores of 1st month didn't show a significant difference between two groups, scores of 3rd month in the high dose MTX group exhibited a marked improvement in all criteria except morning stiffness. Improvements in DAS28 and number of sensitive joints were statistically significant. ACR 20,50,70 and 90 improvements of 3rd month in the high dose MTX group were higher than those of first group. In 2010, a new classification criteria for RA was developed, which makes early diagnosis of RA possible. The treatment includes the use of MTX plus combined DMARDs at the early stages of active disease. Findings of this study demonstrated that usage of high dose MTX at an early stage is more effective in controlling the disease activity and increases the quality of life in RA. Patients receiving high dose metotrexate, needed less treatment change at the end of the 3rd month. Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford). 2004 May;43(5):678-9. Miyasaka N.Paradigm shift and future perspectives in rheumatoid arthritis.Nihon Rinsho. 2013 Jul;71(7):1141-6. Review. Japanese None declared 10.1136/annrheumdis-2014-eular.3135

Disease activity and therapeutic drug monitoring of polyglutamates of methotrexate after daily or weekly administration of low‐dose methotrexate in patients recently diagnosed with rheumatoid arthritis

AB0470 A Research Evaluating the Effectiveness and the Side Effects of High Dose Methotrexate Use in Combined Therapy of Rheumatoid Arthritis

Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis

Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial

Delayed low-dose methotrexate excretion in a rheumatoid arthritis patient: A case report and literature review

Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study

A Double-Blind, Double-Dummy, Randomized Controlled, Multicenter Trial Of Tc-99-Methylene Diphosphonate In Patients With Moderate To Severe Rheumatoid Arthritis

Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence

Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].

Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study

Methotrexate as single therapy in Crohn's disease: Is its long-term efficacy limited?

Overview of Methotrexate Toxicity: A Comprehensive Literature Review

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry

Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial

Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics

Single-cell RNA transcriptomic and plasma Lipidomic reveal the potential mechanisms of a Methotrexate-based therapy against Rheumatoid Arthritis

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients

AB0343 A High Serum Level of Haptoglobin is Associated with the Response of 12 Weeks Methotrexate Therapy in Recent-Onset Rheumatoid Arthritis Patients

Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol